Arbutus Biopharma Corp: A Focus on Chronic Hepatitis B Treatment
Arbutus Biopharma Corporation, a biopharmaceutical company operating within the Health Care sector, has been making strides in the field of Biotechnology. The company is dedicated to discovering, developing, and commercializing drug candidates aimed at treating patients suffering from chronic hepatitis B infection. With its operations primarily based in Canada, Arbutus Biopharma serves both patients and customers in the region and is listed on the Nasdaq stock exchange.
As of August 24, 2025, Arbutus Biopharma’s stock closed at $3.50. Over the past year, the company’s stock has experienced fluctuations, reaching a 52-week high of $4.72 on September 8, 2024, and a 52-week low of $2.71 on April 8, 2025. The company’s market capitalization stands at approximately $686.28 million USD.
Despite its focus on innovative treatments, Arbutus Biopharma’s financial metrics reflect challenges, with a Price Earnings (P/E) ratio of -12.206. This negative P/E ratio indicates that the company is currently not generating profits, which is not uncommon for companies in the biotechnology sector that are heavily invested in research and development.
Arbutus Biopharma’s commitment to addressing chronic hepatitis B is evident in its portfolio of drug candidates. The company continues to focus on advancing its pipeline through rigorous research and development efforts, aiming to bring effective treatments to market.
For more information about Arbutus Biopharma Corporation and its initiatives, interested parties can visit the company’s official website at www.arbutusbio.com .